Age-related macular degeneration causing visual impairment in people 75 years or older in Britain: an add-on study to the Medical Research Council Trial of Assessment and Management of Older People in the Community.
about
Complement inhibitors for age-related macular degenerationComplement inhibitors for age-related macular degenerationDo complement factor H 402Y and C7 M allotypes predispose to (typical) haemolytic uraemic syndrome?Early AMD-like defects in the RPE and retinal degeneration in aged mice with RPE-specific deletion of Atg5 or Atg724-month clinical outcomes of a treat-and-extend regimen with ranibizumab for wet age-related macular degeneration in a real life setting.Risk factors for age-related maculopathyThe prevalence and analysis of risk factors for age-related macular degeneration: 18-year follow-up data from the Speedwell eye study, United Kingdom.Ocular pathology in multiple sclerosis: retinal atrophy and inflammation irrespective of disease duration.Lutein and zeaxanthin intake and the risk of age-related macular degeneration: a systematic review and meta-analysis.Projected changes in age-related macular degeneration and driving license holders in FinlandThe effect of lutein- and zeaxanthin-rich foods v. supplements on macular pigment level and serological markers of endothelial activation, inflammation and oxidation: pilot studies in healthy volunteers.Ocular complications after anti-vascular endothelial growth factor therapy in Medicare patients with age-related macular degenerationMedicare costs for neovascular age-related macular degeneration, 1994-2007.28,000 Cases of age related macular degeneration causing visual loss in people aged 75 years and above in the United Kingdom may be attributable to smoking.Caregiver Burden in Patients Receiving Ranibizumab Therapy for Neovascular Age Related Macular Degeneration.Prevalence of age-related macular degeneration among the elderly.Surgical treatment of age-related macular degeneration: will there be a role in the future?The LOC387715 polymorphism, inflammatory markers, smoking, and age-related macular degeneration. A population-based case-control study.The effect of ranibizumab versus photodynamic therapy on DNA damage in patients with exudative macular degeneration.Associations between chronic kidney disease and age-related macular degeneration.Prognostic implications of imaging in atrophic macular degeneration and its use in clinical practice and clinical trial design.The Pharmacological Effects of Lutein and Zeaxanthin on Visual Disorders and Cognition Diseases.Risk factors and biomarkers of age-related macular degeneration.Prevalence of age-related macular degeneration in an elderly UK Caucasian population-The Bridlington Eye Assessment Project: a cross-sectional study.Circulating markers of arterial thrombosis and late-stage age-related macular degeneration: a case-control study.Current drug and molecular therapies for the treatment of atrophic age-related macular degeneration: phase I to phase III clinical development.Improving hearing and vision in dementia: protocol for a field trial of a new intervention.The introduction of verteporfin photodynamic therapy in the UK: PDT users group (PDTUG) surveillance programme report 1.Does Visual Impairment Affect Social Ties in Late Life? Findings of a Multicenter Prospective Cohort Study in Germany.The economic impact of sight loss and blindness in the UK adult population.Current trends in age-related macular degeneration.
P2860
Q24201117-418A468C-0FC7-4B69-8267-EC74E7381643Q24234636-549ED1B7-6395-4514-BDAE-287F9BFFCA9EQ33395682-06E86C3E-72BD-479B-A9B3-8A2707D15C17Q33585812-C6222C61-8A1E-4713-BE55-849546CB2810Q33612736-D1071260-A348-4144-96F6-0CD4F5110B0CQ33720834-CCA22112-66CD-4314-9229-4B6AA5F03709Q33855388-C725CE0C-C8A4-4BC8-AE8E-22B035C6CC79Q33882723-4C91255C-041A-47AB-8980-EB8BE2166171Q34214289-36F09837-6CAE-465E-8266-2D217A03CA8DQ34274040-14B045C3-9A11-407E-8F4E-CF24BA9E1424Q34635706-784C6839-C4BC-4513-A261-F9640547BA5FQ35127099-7FE52EAB-A751-4335-8EC0-3649149BA8EAQ35560661-7D84567A-F4DD-4A18-BC51-EBFA749F39A0Q35593152-B6D80A34-4392-436B-BB8B-F1A5EB98F70EQ35657801-E01DD5F7-441F-46DE-8C09-04AA3FA49A73Q36294040-D6D41459-D452-46B8-8BF0-76D0C44EF650Q36760432-31E17085-051E-457E-B14F-F27A6FBF67BAQ36922670-914D3070-22E5-4760-B433-3633F3B2E1BEQ37230090-D5A4378B-553C-4C26-BA98-035BC468465EQ37479341-B75660A5-8BCC-4D6E-B04E-006F634C1542Q38607697-A93910B5-7E85-435B-B817-A0809D5A5095Q38692816-546172A0-1666-48D1-8B38-2FA43061E383Q38828895-A1414D95-C80D-443C-A1CF-05013B7CB05CQ38915036-1D72A160-C5E8-47A0-8A94-2F4045E72D04Q43164515-2017308B-53F2-46FC-8217-0F1BCA6E4E75Q45870879-0AD64227-4903-44C1-A49A-C0FF1E2B77EFQ47120248-D01A0F74-34A5-412B-ACB2-3A01B4A4D428Q47579315-4638A7B6-BE3F-4C3C-8A80-64068C2DAE7EQ47858501-6CC3B7FE-C6B1-45A8-A00A-9FEC20C2DD77Q48139906-4A8FD673-B5F4-488B-B5DA-D4FA1D397611Q53116825-3648610F-6906-46C9-A350-A26A5D8049AF
P2860
Age-related macular degeneration causing visual impairment in people 75 years or older in Britain: an add-on study to the Medical Research Council Trial of Assessment and Management of Older People in the Community.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
2004年论文
@zh
2004年论文
@zh-cn
name
Age-related macular degenerati ...... Older People in the Community.
@ast
Age-related macular degenerati ...... Older People in the Community.
@en
type
label
Age-related macular degenerati ...... Older People in the Community.
@ast
Age-related macular degenerati ...... Older People in the Community.
@en
prefLabel
Age-related macular degenerati ...... Older People in the Community.
@ast
Age-related macular degenerati ...... Older People in the Community.
@en
P2093
P1433
P1476
Age-related macular degenerati ...... Older People in the Community.
@en
P2093
Astrid E Fletcher
Jennifer R Evans
Richard P L Wormald
P304
P356
10.1016/J.OPHTHA.2003.07.012
P577
2004-03-01T00:00:00Z